Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole

被引：19

作者：

Bellone, Stefania ^{[1
]}

Shah, Hemendrah R. ^{[2
]}

McKenney, Jesse K. ^{[3
]}

Stone, Pamela J. B. ^{[2
]}

Santin, Alessandro D. ^{[1
]}

机构：

[1] Yale Univ, Sch Med, Dept Obstet & Gynecol, Div Gynecol Oncol, New Haven, CT 06520 USA

[2] Univ Arkansas, Dept Radiol, Little Rock, AR 72204 USA

[3] Univ Arkansas, Dept Pathol, Little Rock, AR 72204 USA

来源：

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY | 2008年 / 199卷 / 03期

关键词：

anastrozole; aromatase inhibitor; endometrial carcinoma; estrogen receptor;

D O I：

10.1016/j.ajog.2008.04.012

中图分类号：

R71 [妇产科学];

学科分类号：

100211 [妇产科学];

摘要：

Recurrent/metastatic endometrial adenocarcinoma that is not amenable to cure with local or regional therapy and/or chemotherapy represents a discouraging clinical entity for the clinician. We report the case of 58-year-old woman with recurrent endometrial carcinoma that was resistant to chemotherapy that was treated successfully with the aromatase inhibitor anastrozole.

引用

页码：E7 / E10

页数：4

共 11 条

[1]

[Anonymous], CLIN GYNECOLOGIC ONC

[2]

Systemic chemotherapy for uterine carcinoma: Metastatic and adjuvant [J].